



(12) Translation of
European patent specification

(11) NO/EP 2694544 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/38 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.06.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.01.23
(86)	European Application Nr.	12762959.0
(86)	European Filing Date	2012.03.30
(87)	The European Application's Publication Date	2014.02.12
(30)	Priority	2011.04.01, US, 201161471101 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Bayer HealthCare LLC, 100 Bayer Boulevard, Whippany, NJ 07981-0915, USA
(72)	Inventor	WANG, Zhuozhi, Unit 383 1388 Broadway, Millbrae California 94030, USA MURPHY, John, 1139 The Alameda, Berkeley California 94707, USA MARQUARDT, Tobias, Viktoriastrasse 81, 42115 Wuppertal, Tyskland MOOSMAYER, Dieter, Wöhlertstrasse 11, 10115 Berlin, Tyskland
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI)**

(56) References
Cited: WO-A1-2011/109452
WO-A2-2010/017196
WO-A1-2010/072691
DATABASE UNIPROT [Online] 01 July 1989 XP003032876 Database accession no. P10646
GIRARD T J ET AL: "FUNCTIONAL SIGNIFICANCE OF THE KUNITZ-TYPE INHIBITORY
DOMAINS OF LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR", NATURE,
MACMILLAN JOURNALS LTD., ETC., vol. 338, 1 April 1989 (1989-04-01), pages 518-520,
XP000857349, ISSN: 0028-0836, DOI: 10.1038/338518A0
LWALEED BASHIR A ET AL: "Tissue factor pathway inhibitor: structure, biology and
involvement in disease", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol.
208, no. 3, 1 February 2006 (2006-02-01), pages 327-339, XP002517694, ISSN: 0022-3417,
DOI: 10.1002/PATH.1871 [retrieved on 2005-11-01]
STEPHAN DUEBEL ED - STEFAN DÜBEL: "Handbook of Therapeutic Antibodies Chapter 6", 1
January 2007 (2007-01-01), HANDBOOK OF THERAPEUTIC ANTIBO, WILEY-VCH,
WEINHEIM, PAGE(S) 119 - 144, XP007913671, ISBN: 978-3-527-31453-9

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Et isolert monoklonalt antistoff som binder til en epitop av human TFPI (Tissue Factor Pathway Inhibitor) (SEQ ID NO: 1),
- 5 hvor nevnte epitop omfatter én eller flere rester av Kunitz-domene 1, valgt fra gruppen bestående av Asp31, Asp32, Gly33, Pro34, Cys35, Lys36, Cys59, Glu60 og Asn62, og hvor nevnte epitop omfatter én eller flere rester av Kunitz-domene 2, valgt fra gruppen bestående av Glu100, Glu101, Pro103, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Phe114, Asn116, Glu123, Arg124, Lys126, Tyr127 og Gly128 og hvor det isolerte
- 10 monoklonale antistoffet omfatter en variabel lettkjede (V_L) av SEQ ID NO: 4 og en variabel tungkjede (V_H) av SEQ ID NO: 5.

2. En farmasøytisk sammensetning omfattende en terapeutisk effektiv mengde av det monoklonale antistoff ifølge krav 1 og en farmasøytisk akseptabel bærer.